The UK CMA says it will open an in-depth investigation into Getty and Shutterstock's proposed merger after their offered remedies did not fully address concerns
Raechel Thankam Job / Reuters :
Context & Ripple Effects
The escalation follows the CMA’s earlier finding that the $3.7B transaction raised competition issues and its request for a corrective plan; the parties’ response has now failed to resolve those concerns. The earlier CMA concerns notice made clear that a deeper review was possible.
This fits a recent CMA pattern in which proposed remedies do not necessarily avert a full merger inquiry, as seen in its in-depth review of Adobe’s proposed Figma acquisition. The later record indicates the dispute ultimately centered on a required divestment of Shutterstock’s editorial business. Getty later ended the transaction after that condition
First-order effects
- Getty and Shutterstock move into a more intensive CMA review, extending regulatory uncertainty around the proposed combination.
- The companies must either develop remedies that satisfy the CMA or prepare for the possibility that the deal cannot proceed on its proposed terms.
Second-order effects
- A remedy process can reshape the transaction’s economics by requiring asset sales or other constraints, rather than simply deciding whether the merger closes.
- Other large media and creative-market dealmakers have a clearer signal that initial concessions may not prevent the CMA from demanding a detailed competitive assessment.
Third-order effects
- If this enforcement pattern persists, UK merger review will exert greater influence over the structure of digital-content markets, particularly where consolidation concentrates important image and editorial libraries.
- The outcome will help test whether divestitures can preserve competition in a market being reshaped by AI-related changes, or whether regulators will prefer tougher limits on consolidation.
The trend: Competition authorities are applying closer scrutiny to consolidation among digital-content and creative-industry platforms, with remedies increasingly becoming a central determinant of deal viability.